Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 4/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | DRD5 | P21918 | 2/20 | 0.52 |
| ▸ | HRH2 | P25021 | 2/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22951229 | 0.88 | CACNA1B (0.78) | CACNA1BCACNA1CCACNA1FDRD4DRD5 | |
| SCHEMBL4386075 | 0.80 | CACNA1B (0.66) | CACNA1BCACNA1CCACNA1FDRD4DRD5 | |
| SCHEMBL4277600 | 0.76 | CACNA1B (0.60) | CACNA1BCACNA1CCACNA1FDRD4DRD5 | |
| SCHEMBL14115762 | 0.76 | POLB (0.61) | CACNA1BKMT2A | |
| SCHEMBL5633412 | 0.75 | KCNH2 (0.62) | CACNA1BCACNA1CCACNA1FDRD4DRD5 | |
| SCHEMBL4282408 | 0.73 | CACNA1B (0.56) | CACNA1BHTR2AHTR2CKCNH2 | |
| SCHEMBL31370057 | 0.72 | CACNA1B (0.56) | CACNA1BKMT2ADPP4DPP8 | |
| SCHEMBL5675574 | 0.72 | CACNA1F (0.57) | CACNA1BCACNA1CCACNA1FDRD4DRD5 | |
| SCHEMBL4150889 | 0.71 | GNAI3 (0.57) | CACNA1BDPP4DPP9DPP8 | |
| SCHEMBL2862307 | 0.71 | CACNA1B (0.54) | CACNA1BCACNA1CCACNA1FDRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210030695-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-02-04 | — | — | US | disclosed |
| US-10729664-B2 | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190216747-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION | 2019-07-18 | — | — | US | disclosed |
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | THE GENERAL HOSPITAL CORPORATION | 2012-07-05 | — | — | US | disclosed |
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | THE GENERAL HOSPITAL CORPORATION | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | CACNA1B 2/4885CACNA1C 4/4885CACNA1F 6/4885 |
| US-10729664-B2 | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents | TRPV1, CACNA1B, ORAI1 | CACNA1B 2/4885CACNA1C 4/4885CACNA1F 6/4885 |
| US-20210030695-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | CACNA1B 2/4885CACNA1C 4/4885CACNA1F 6/4885 |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | CACNA1B 33/4885CACNA1C 84/4885CACNA1F 82/4885 |
| US-20190216747-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | CACNA1B 2/4885CACNA1C 4/4885CACNA1F 6/4885 |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | CACNA1B 2/4885CACNA1C 4/4885CACNA1F 6/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | CACNA1B 1/4885CACNA1C 4/4885CACNA1F 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.